BDTX vs. AURA, TNYA, SLDB, OCGN, TRML, MGTX, JSPR, TCRX, CRBU, and REPL
Should you be buying Black Diamond Therapeutics stock or one of its competitors? The main competitors of Black Diamond Therapeutics include Aura Biosciences (AURA), Tenaya Therapeutics (TNYA), Solid Biosciences (SLDB), Ocugen (OCGN), Tourmaline Bio (TRML), MeiraGTx (MGTX), Jasper Therapeutics (JSPR), TScan Therapeutics (TCRX), Caribou Biosciences (CRBU), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.
Black Diamond Therapeutics (NASDAQ:BDTX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
Black Diamond Therapeutics has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.
Black Diamond Therapeutics currently has a consensus target price of $12.25, indicating a potential upside of 106.23%. Aura Biosciences has a consensus target price of $21.00, indicating a potential upside of 192.48%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Black Diamond Therapeutics.
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 10 mentions for Black Diamond Therapeutics and 9 mentions for Aura Biosciences. Black Diamond Therapeutics' average media sentiment score of 1.04 beat Aura Biosciences' score of 0.82 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.
Aura Biosciences' return on equity of -41.79% beat Black Diamond Therapeutics' return on equity.
Aura Biosciences is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Black Diamond Therapeutics received 26 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 63.33% of users gave Black Diamond Therapeutics an outperform vote while only 46.15% of users gave Aura Biosciences an outperform vote.
Summary
Black Diamond Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.
Get Black Diamond Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Black Diamond Therapeutics Competitors List
Related Companies and Tools
